How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population.
All News
Article
Article
Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m2) with
Article
Pain Persists in RA, Even Without Inflammation
MedPage Today
One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
Article
With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.
The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu
Danish population study shows that all cause mortality in GCA is increased 49%,(RR 1.49; CI1.36-1.64) after 1 year but less so at 10 years (RR 1.03: 1.00-1.05). Deaths usually due to infectious, endocrine, cardiovascular, GI diseases https://t.co/p36zDskf6y
RHEUMATOLOGIST SURVEY - on Osteoporosis, Osteomalacia and a Family Hx of recurrent Fractures - Answer a 4 question survey here >>
https://t.co/TuY1fXAAk5
Guidelines for the prevention, diagnosis and treatment of Lyme disease have been formulated by the ACR, Infectious Diseases Society of America and the American Academy of Neurology https://t.co/RgHzCLrtDM
The Swedish Rheumatology Quality Register looked at risk of ant.uveitis (AU). From 4851 starting secukinumab (456) or TNFinhibitor (4395 ), there was higher AU risk w/ SEC (adj HR 2.32; 1.16-4.63) & ETN (1.82;1.13-2.93) (ADA as referent) https://t.co/j06MtKedYU
Metanalysis shows no clear association between allopurinol use and a lowered all-cause mortality in gout patients, but the number of studies was small https://t.co/MM0nIjZPbV
Italian survey foud 82% of MSK healthcare workers willing to receive COVID-19 vaccine, but only 55% of their rheumatic Dz patients were as willing, even if they perceived they were at risk. Not out of fear or distrust. more education needed https://t.co/nPhhME2dnC
66 yoF w/ prurtitic rash, weakness, SOB, hyperpigmented papules over knuckles, periungual hemorrhages, shawl like rash and the Holster sign (lateral thighs). Which drugs would you use:
A. Steroids
B. IVIG
C. MMF
D. Baricitinib
E. Plasmapheresis
https://t.co/IA4qbGri5b
Is there a connection between stress and the onset of RA?
https://t.co/Oir9ZV3m7i https://t.co/GTpvTCiMAP
Rheumatologist Survey - A man with osteoporosis and recurrent fractures - What should test for ? Phosphorous, testosterone, magnesium or HLA-B27; answer here> https://t.co/TuY1fXAAk5
Miss out on something from EULAR?
Check out our daily recaps.
https://t.co/seKFd36te4 https://t.co/O1Of0ThRjS
Watch our video on the three new medications for lupus.
https://t.co/IrHEJdpHqK https://t.co/ox7YNU2fFe
French Vasculitis registry studied 354 GPA patients- 25% had hypereosinophilia (HE) ≥ 500; mostly male (73%) w/ most skin dz (49%) peripheral neuropathy (32%) & higher BVAS (21 vs 18, p= 0.01): severe HE had more baseline renal dysfunction https://t.co/G4s3CEavL9
Enthesitis is a tricky and unclear topic. Dr. Robert Chao ( @doctorRBC ) shares #EULAR2021 learnings.
https://t.co/pZRMZtbJAh https://t.co/kQEKveZFnY
What do Rheumatologists Know about XLH? Here's a four question Survey for Rheumatologists on a rare disorder - https://t.co/TuY1fXAAk5
FINCH 1 Trial Filgotinib in Rheumatoid Arthritis
The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the JAK1 preferential inhibitor filgotinib was superior to adalimumab in active RA on MTX.
https://t.co/d501qhArfP https://t.co/YGH5LQDGbs


